Implementation of New Models of Ovarian Carcinoma Resistant to Therapy
1 other identifier
observational
50
0 countries
N/A
Brief Summary
The project focuses on developing new experimental models of ovarian cancer that accurately reflect patients who do not respond to first-line platinum-based treatments and who are resistant to PARP inhibitors (PARPi). These models are essential for testing new drugs or drug combinations in preclinical settings that closely mimic real clinical conditions. These models will also help to identify predictive biomarkers of treatment response and to better understand the biological mechanisms behind therapy resistance.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2026
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 26, 2026
CompletedStudy Start
First participant enrolled
August 1, 2026
CompletedFirst Posted
Study publicly available on registry
August 11, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2036
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2036
August 11, 2026
August 1, 2026
10.1 years
March 26, 2026
August 5, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
To obtain new in vivo experimental models of ovarian carcinomas
To obtain new experimental models from biopsies of ovarian carcinomas that are refractory to platinum-based therapy and recurrent during or after treatment with platinum-based therapy and PARP inhibitors, as treated at the Division of Medical Gynecologic Oncology of the European Institute of Oncology. To this end, a portion of the neoplastic tissue will be transplanted subcutaneously into at least two immunodeficient mice and follwed for tumor appearance
10 years
To obtain new in vitro experimental models of ovarian carcinomas
To obtain new experimental models from biopsies of ovarian carcinomas that are refractory to platinum-based therapy and recurrent during or after treatment with platinum-based therapy and PARP inhibitors, as treated at the Division of Medical Gynecologic Oncology of the European Institute of Oncology. To this end, a portion of the neoplastic tissue will digest with collagesase and single cell suspension obtained and seeded with specific mediums suplemented with growth factors in vitro to obtain primary cultures and organoids
10 years
Secondary Outcomes (5)
Pharmacological characterization of the obtained models: in vivo outcomes
10 years
Pharmacological characterization of the obtained models: in vivo outcomes
10 years
Pharmacological characterization of the obtained models: in vitro outcomes
10 years
Molecular identification of potential biomarker of response
10 years
Molecular identification of potential biomarker of response
10 years
Study Arms (1)
Patients with ovarian carcinoma
Patients with ovarian carcinoma resistant to platinum drugs and PARPi
Interventions
Patients with ovarian carcinoma resistant to platinum drugs and PARPi undergoing paracentasis and/or surgical with left-over tumor material.
Eligibility Criteria
Female with malignant gynecological cancers of ovarian origin refractory to platinum-based therapy or recurring during or after treatment with platinum and PARP inhibitors.
You may qualify if:
- Female patients with malignant ovarian gynecological disease.
- Age 18 years or older.
- Patients capable of providing informed consent.
You may not qualify if:
- Failure to sign the informed consent form.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
Tumor samples and ascites
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 26, 2026
First Posted
August 11, 2026
Study Start
August 1, 2026
Primary Completion (Estimated)
August 31, 2036
Study Completion (Estimated)
August 31, 2036
Last Updated
August 11, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share
This is a biological study involving the transplantation of fresh tumor tissue into immunodeficient mice to generate new patient-derived xenograft (PDX) models of ovarian origin and new in vitro models. The study plans to enroll patients admitted to the Division of Medical Gynecologic Oncology at the European Institute of Oncology who have malignant gynecologic diseases of ovarian origin that are refractory to platinum-based therapy or have recurred during or after treatment with platinum and PARP inhibitors.